Nair JR - Search Results

1

AKT1 interacts with DHX9 to Mitigate R Loop-Induced Replication Stress in Ovarian Cancer.

Huang TT, Chiang CY, Nair JR, Wilson KM, Cheng K, Lee JM. Huang TT, et al. Among authors: nair jr. Cancer Res. 2024 Mar 15;84(6):887-904. doi: 10.1158/0008-5472.CAN-23-1908. Cancer Res. 2024. PMID: 38241710 Free PMC article.

2

Prexasertib, a cell cycle checkpoint kinases 1 and 2 inhibitor, increases in vitro toxicity of PARP inhibition by preventing Rad51 foci formation in BRCA wild type high-grade serous ovarian cancer.

Brill E, Yokoyama T, Nair J, Yu M, Ahn YR, Lee JM. Brill E, et al. Oncotarget. 2017 Oct 31;8(67):111026-111040. doi: 10.18632/oncotarget.22195. eCollection 2017 Dec 19. Oncotarget. 2017. PMID: 29340034 Free PMC article.

3

Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study.

Lee JM, Nair J, Zimmer A, Lipkowitz S, Annunziata CM, Merino MJ, Swisher EM, Harrell MI, Trepel JB, Lee MJ, Bagheri MH, Botesteanu DA, Steinberg SM, Minasian L, Ekwede I, Kohn EC. Lee JM, et al. Lancet Oncol. 2018 Feb;19(2):207-215. doi: 10.1016/S1470-2045(18)30009-3. Epub 2018 Jan 18. Lancet Oncol. 2018. PMID: 29361470 Free PMC article.

4

Patients with BRCA mutated ovarian cancer may have fewer circulating MDSC and more peripheral CD8⁺ T cells compared with women with BRCA wild-type disease during the early disease course.

Lee JM, Botesteanu DA, Tomita Y, Yuno A, Lee MJ, Kohn EC, Annunziata CM, Matulonis U, MacDonald LA, Nair JR, Macneill KM, Trepel JB. Lee JM, et al. Among authors: nair jr. Oncol Lett. 2019 Oct;18(4):3914-3924. doi: 10.3892/ol.2019.10731. Epub 2019 Aug 7. Oncol Lett. 2019. PMID: 31516602 Free PMC article.

5

Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study.

Lampert EJ, Zimmer A, Padget M, Cimino-Mathews A, Nair JR, Liu Y, Swisher EM, Hodge JW, Nixon AB, Nichols E, Bagheri MH, Levy E, Radke MR, Lipkowitz S, Annunziata CM, Taube JM, Steinberg SM, Lee JM. Lampert EJ, et al. Among authors: nair jr. Clin Cancer Res. 2020 Aug 15;26(16):4268-4279. doi: 10.1158/1078-0432.CCR-20-0056. Epub 2020 May 12. Clin Cancer Res. 2020. PMID: 32398324 Free PMC article. Clinical Trial.

6

A Phase II Single Arm Pilot Study of the CHK1 Inhibitor Prexasertib (LY2606368) in BRCA Wild-Type, Advanced Triple-Negative Breast Cancer.

Gatti-Mays ME, Karzai FH, Soltani SN, Zimmer A, Green JE, Lee MJ, Trepel JB, Yuno A, Lipkowitz S, Nair J, McCoy A, Lee JM. Gatti-Mays ME, et al. Oncologist. 2020 Dec;25(12):1013-e1824. doi: 10.1634/theoncologist.2020-0491. Epub 2020 Jun 24. Oncologist. 2020. PMID: 32510664 Free PMC article. Clinical Trial.

7

Resistance to the CHK1 inhibitor prexasertib involves functionally distinct CHK1 activities in BRCA wild-type ovarian cancer.

Nair J, Huang TT, Murai J, Haynes B, Steeg PS, Pommier Y, Lee JM. Nair J, et al. Oncogene. 2020 Aug;39(33):5520-5535. doi: 10.1038/s41388-020-1383-4. Epub 2020 Jul 9. Oncogene. 2020. PMID: 32647134 Free PMC article.

8

Clinical outcomes of prexasertib monotherapy in recurrent BRCA wild-type high-grade serous ovarian cancer involve innate and adaptive immune responses.

Lampert EJ, Cimino-Mathews A, Lee JS, Nair J, Lee MJ, Yuno A, An D, Trepel JB, Ruppin E, Lee JM. Lampert EJ, et al. J Immunother Cancer. 2020 Jul;8(2):e000516. doi: 10.1136/jitc-2019-000516. J Immunother Cancer. 2020. PMID: 32709712 Free PMC article. Clinical Trial.

9

Targeting the PI3K/mTOR Pathway Augments CHK1 Inhibitor-Induced Replication Stress and Antitumor Activity in High-Grade Serous Ovarian Cancer.

Huang TT, Brill E, Nair JR, Zhang X, Wilson KM, Chen L, Thomas CJ, Lee JM. Huang TT, et al. Among authors: nair jr. Cancer Res. 2020 Dec 1;80(23):5380-5392. doi: 10.1158/0008-5472.CAN-20-1439. Epub 2020 Sep 30. Cancer Res. 2020. PMID: 32998994 Free PMC article.

10

Distinct roles of treatment schemes and BRCA2 on the restoration of homologous recombination DNA repair and PARP inhibitor resistance in ovarian cancer.

Huang TT, Burkett SS, Tandon M, Yamamoto TM, Gupta N, Bitler BG, Lee JM, Nair JR. Huang TT, et al. Among authors: nair jr. Oncogene. 2022 Nov;41(46):5020-5031. doi: 10.1038/s41388-022-02491-8. Epub 2022 Oct 12. Oncogene. 2022. PMID: 36224341 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

69 results

Search Page

Filters